Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Current Oncology (Toronto, Ont.)|July 25, 2025
HIV Integration into the PTEN Gene and Its Tumor Microenvironment Implications for Lung CancerDavey M Smith, Elizabeth F Rowland, Sara Gianella, et al.
Frontiers in Immunology|May 2, 2022
CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung CancerClaire Olingy, Ahmad Alimadadi, Daniel J Araujo, et al.
Case Reports in Oncology|October 30, 2024
A Complete Response to Combined Immunotherapy in a Patient with an ATM plus SF3B1 Mutation and a Moderate Tumor Mutational Burden with a High-Grade Treatment-Emergent Neuroendocrine Prostate Cancer: Case Report and Review of the LiteratureHelena Ferreira Bruzzi Porto, Gabriela C K Lopes, Hannah B V Bekierman, et al.
Cancer Research Communications|October 15, 2025
Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid TumorsLisa Gai, Bradley Bowles, Adam J Hockenberry, et al.
Molecular Genetics and Metabolism|June 29, 2015
Non-invasive pulmonary function test on Morquio patientsFrancyne Kubaski, Shunji Tomatsu, Pravin Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or LymphomasJason J Luke, Randy F Sweis, J Randolph Hecht, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2025
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancerByoung Chul Cho, Chaiyut Charoentum, Dong-Wan Kim, et al.
Breast (Edinburgh, Scotland)|January 5, 2019
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytesNancy Tray, Jessica Taff, Baljit Singh, et al.
Molecular Genetics and Metabolism|December 4, 2014
Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantationJulian Tanjuakio, Yasuyuki Suzuki, Pravin Patel, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
Pageof 11